These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 23088608)

  • 1. Target Selectivity of FimH Antagonists.
    Scharenberg M; Schwardt O; Rabbani S; Ernst B
    J Med Chem; 2012 Nov; 55(22):9810-6. PubMed ID: 23088608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation.
    Klein T; Abgottspon D; Wittwer M; Rabbani S; Herold J; Jiang X; Kleeb S; Lüthi C; Scharenberg M; Bezençon J; Gubler E; Pang L; Smiesko M; Cutting B; Schwardt O; Ernst B
    J Med Chem; 2010 Dec; 53(24):8627-41. PubMed ID: 21105658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Bouckaert J; Berglund J; Schembri M; De Genst E; Cools L; Wuhrer M; Hung CS; Pinkner J; Slättegård R; Zavialov A; Choudhury D; Langermann S; Hultgren SJ; Wyns L; Klemm P; Oscarson S; Knight SD; De Greve H
    Mol Microbiol; 2005 Jan; 55(2):441-55. PubMed ID: 15659162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists.
    Schwardt O; Rabbani S; Hartmann M; Abgottspon D; Wittwer M; Kleeb S; Zalewski A; Smieško M; Cutting B; Ernst B
    Bioorg Med Chem; 2011 Nov; 19(21):6454-73. PubMed ID: 21962988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FimH antagonists: structure-activity and structure-property relationships for biphenyl α-D-mannopyranosides.
    Pang L; Kleeb S; Lemme K; Rabbani S; Scharenberg M; Zalewski A; Schädler F; Schwardt O; Ernst B
    ChemMedChem; 2012 Aug; 7(8):1404-22. PubMed ID: 22644941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A flow cytometry-based assay for screening FimH antagonists.
    Scharenberg M; Abgottspon D; Cicek E; Jiang X; Schwardt O; Rabbani S; Ernst B
    Assay Drug Dev Technol; 2011 Oct; 9(5):455-64. PubMed ID: 21675870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational design strategies for FimH antagonists: new drugs on the horizon for urinary tract infection and Crohn's disease.
    Mydock-McGrane LK; Hannan TJ; Janetka JW
    Expert Opin Drug Discov; 2017 Jul; 12(7):711-731. PubMed ID: 28506090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FimH antagonists: bioisosteres to improve the in vitro and in vivo PK/PD profile.
    Kleeb S; Pang L; Mayer K; Eris D; Sigl A; Preston RC; Zihlmann P; Sharpe T; Jakob RP; Abgottspon D; Hutter AS; Scharenberg M; Jiang X; Navarra G; Rabbani S; Smiesko M; Lüdin N; Bezençon J; Schwardt O; Maier T; Ernst B
    J Med Chem; 2015 Mar; 58(5):2221-39. PubMed ID: 25666045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.
    Jarvis C; Han Z; Kalas V; Klein R; Pinkner JS; Ford B; Binkley J; Cusumano CK; Cusumano Z; Mydock-McGrane L; Hultgren SJ; Janetka JW
    ChemMedChem; 2016 Feb; 11(4):367-73. PubMed ID: 26812660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic properties of carbohydrate-lectin interactions: FimH antagonists.
    Scharenberg M; Jiang X; Pang L; Navarra G; Rabbani S; Binder F; Schwardt O; Ernst B
    ChemMedChem; 2014 Jan; 9(1):78-83. PubMed ID: 24357503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH.
    Wellens A; Lahmann M; Touaibia M; Vaucher J; Oscarson S; Roy R; Remaut H; Bouckaert J
    Biochemistry; 2012 Jun; 51(24):4790-9. PubMed ID: 22657089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiadhesion therapy for urinary tract infections--a balanced PK/PD profile proved to be key for success.
    Jiang X; Abgottspon D; Kleeb S; Rabbani S; Scharenberg M; Wittwer M; Haug M; Schwardt O; Ernst B
    J Med Chem; 2012 May; 55(10):4700-13. PubMed ID: 22519985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.
    Mydock-McGrane LK; Cusumano ZT; Janetka JW
    Expert Opin Ther Pat; 2016; 26(2):175-97. PubMed ID: 26651364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective depletion of uropathogenic E. coli from the gut by a FimH antagonist.
    Spaulding CN; Klein RD; Ruer S; Kau AL; Schreiber HL; Cusumano ZT; Dodson KW; Pinkner JS; Fremont DH; Janetka JW; Remaut H; Gordon JI; Hultgren SJ
    Nature; 2017 Jun; 546(7659):528-532. PubMed ID: 28614296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of thiomannosides, potent and orally active FimH inhibitors.
    Sattigeri JA; Garg M; Bhateja P; Soni A; Rauf ARA; Gupta M; Deshmukh MS; Jain T; Alekar N; Barman TK; Jha P; Chaira T; Bambal RB; Upadhyay DJ; Nishi T
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2993-2997. PubMed ID: 30017316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Conformational Variability of FimH: Which Conformation Represents the Therapeutic Target?
    Eris D; Preston RC; Scharenberg M; Hulliger F; Abgottspon D; Pang L; Jiang X; Schwardt O; Ernst B
    Chembiochem; 2016 Jun; 17(11):1012-20. PubMed ID: 26991759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.
    Ratliff TL
    J Urol; 2005 Sep; 174(3):1150. PubMed ID: 16094085
    [No Abstract]   [Full Text] [Related]  

  • 18. The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes.
    Bouckaert J; Mackenzie J; de Paz JL; Chipwaza B; Choudhury D; Zavialov A; Mannerstedt K; Anderson J; Piérard D; Wyns L; Seeberger PH; Oscarson S; De Greve H; Knight SD
    Mol Microbiol; 2006 Sep; 61(6):1556-68. PubMed ID: 16930149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.
    Greene SE; Hibbing ME; Janetka J; Chen SL; Hultgren SJ
    mBio; 2015 Jun; 6(4):e00820. PubMed ID: 26126855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biofilm formation in a hydrodynamic environment by novel fimh variants and ramifications for virulence.
    Schembri MA; Klemm P
    Infect Immun; 2001 Mar; 69(3):1322-8. PubMed ID: 11179294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.